NASDAQ:VNDA

Vanda Pharmaceuticals Stock News

etoro logo Buy VNDA
*Your capital is at risk
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Kevin Moran - SVP, CFO and Treasurer Dr. Mihael Polymeropoulos - President, C
Vanda Pharmaceuticals (VNDA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.06 per share a year ago.
WASHINGTON , Sept. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
Vanda is being dropped from the S&P 600 SmallCap 600. The company is suing the federal government over what it says was the release of trade secrets regarding its therapies.
The heavy selling pressure might have exhausted for Vanda (VNDA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r
Conference Call and Webcast to Follow WASHINGTON , July 20, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2023 o
Conference Call and Webcast to Follow WASHINGTON , April 27, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2023 o
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q4 2022 Earnings Conference Call February 8, 2023 4:30 AM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, CEO and Chairman Timoth
Conference Call and Webcast to Follow WASHINGTON , Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and ful
WASHINGTON , Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Kevin Moran - Senior Vice President & Chief Financial Officer Mihael Polymer
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Conference Call and Webcast to Follow WASHINGTON , Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on

Vanda: VPO-227 Advancement Signals More Upsides

01:45pm, Tuesday, 25'th Oct 2022
From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales. The company recently planted long-term growth via the OliPas partnership for ASO deve
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE